cardiac fibroblasts Search Results


97
PromoCell primary human cardiac fibroblasts
Primary Human Cardiac Fibroblasts, supplied by PromoCell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary human cardiac fibroblasts/product/PromoCell
Average 97 stars, based on 1 article reviews
primary human cardiac fibroblasts - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

96
Cell Applications Inc muscle cell basal medium cell applications
Muscle Cell Basal Medium Cell Applications, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/muscle cell basal medium cell applications/product/Cell Applications Inc
Average 96 stars, based on 1 article reviews
muscle cell basal medium cell applications - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

93
Cell Applications Inc cardiac fibroblast growth medium
Cardiac Fibroblast Growth Medium, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cardiac fibroblast growth medium/product/Cell Applications Inc
Average 93 stars, based on 1 article reviews
cardiac fibroblast growth medium - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

95
Cell Applications Inc fetal human cardiac fibroblasts cfs
Versican ( VCAN ) expression is regulated by cytokines and mechanical stretch in cardiac cells. (A) mRNA expression of versican was upregulated by TGF-β1, and downregulated by TNF-α, and IL-1β in cardiac <t>fibroblasts,</t> and (B) in addition by IL-4 in cardiomyocytes compared to control (Control, n = 3). (C, D) Versican and α-SMA ( ACTA2 ) mRNA expression were increased after biaxial strain of 10% (stretch) for 24 h at 1 Hz frequency in fibroblasts compared to non-stretched cells (Control, n = 9). Gene expression is presented as values relative to Control. Bar graphs represent mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test (A, B) and Student’s t -test (C, D) were used for statistical analysis. P values < 0.05 were considered statistically significant. *P < 0.05 Control vs. cytokine treatment or stretch.
Fetal Human Cardiac Fibroblasts Cfs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fetal human cardiac fibroblasts cfs/product/Cell Applications Inc
Average 95 stars, based on 1 article reviews
fetal human cardiac fibroblasts cfs - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

93
Innoprot Inc human cardiac fibroblasts heart
Versican ( VCAN ) expression is regulated by cytokines and mechanical stretch in cardiac cells. (A) mRNA expression of versican was upregulated by TGF-β1, and downregulated by TNF-α, and IL-1β in cardiac <t>fibroblasts,</t> and (B) in addition by IL-4 in cardiomyocytes compared to control (Control, n = 3). (C, D) Versican and α-SMA ( ACTA2 ) mRNA expression were increased after biaxial strain of 10% (stretch) for 24 h at 1 Hz frequency in fibroblasts compared to non-stretched cells (Control, n = 9). Gene expression is presented as values relative to Control. Bar graphs represent mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test (A, B) and Student’s t -test (C, D) were used for statistical analysis. P values < 0.05 were considered statistically significant. *P < 0.05 Control vs. cytokine treatment or stretch.
Human Cardiac Fibroblasts Heart, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiac fibroblasts heart/product/Innoprot Inc
Average 93 stars, based on 1 article reviews
human cardiac fibroblasts heart - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Miltenyi Biotec neonatal cardiac fibroblast cell isolation kit
a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 <t>fibroblast,</t> 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).
Neonatal Cardiac Fibroblast Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/neonatal cardiac fibroblast cell isolation kit/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
neonatal cardiac fibroblast cell isolation kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Cell Applications Inc rat cardiac fibroblasts
a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 <t>fibroblast,</t> 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).
Rat Cardiac Fibroblasts, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat cardiac fibroblasts/product/Cell Applications Inc
Average 93 stars, based on 1 article reviews
rat cardiac fibroblasts - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

91
Innoprot Inc cardiac fibroblasts
a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 <t>fibroblast,</t> 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).
Cardiac Fibroblasts, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cardiac fibroblasts/product/Innoprot Inc
Average 91 stars, based on 1 article reviews
cardiac fibroblasts - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

94
iXCells Biotechnologies cat 10mu 015 san diego
a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 <t>fibroblast,</t> 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).
Cat 10mu 015 San Diego, supplied by iXCells Biotechnologies, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cat 10mu 015 san diego/product/iXCells Biotechnologies
Average 94 stars, based on 1 article reviews
cat 10mu 015 san diego - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec neonatal cardiac fibroblast isolation kit
a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 <t>fibroblast,</t> 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).
Neonatal Cardiac Fibroblast Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/neonatal cardiac fibroblast isolation kit/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
neonatal cardiac fibroblast isolation kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

95
PromoCell vitro treatment human primary cardiac fibroblasts cf
a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 <t>fibroblast,</t> 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).
Vitro Treatment Human Primary Cardiac Fibroblasts Cf, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vitro treatment human primary cardiac fibroblasts cf/product/PromoCell
Average 95 stars, based on 1 article reviews
vitro treatment human primary cardiac fibroblasts cf - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Versican ( VCAN ) expression is regulated by cytokines and mechanical stretch in cardiac cells. (A) mRNA expression of versican was upregulated by TGF-β1, and downregulated by TNF-α, and IL-1β in cardiac fibroblasts, and (B) in addition by IL-4 in cardiomyocytes compared to control (Control, n = 3). (C, D) Versican and α-SMA ( ACTA2 ) mRNA expression were increased after biaxial strain of 10% (stretch) for 24 h at 1 Hz frequency in fibroblasts compared to non-stretched cells (Control, n = 9). Gene expression is presented as values relative to Control. Bar graphs represent mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test (A, B) and Student’s t -test (C, D) were used for statistical analysis. P values < 0.05 were considered statistically significant. *P < 0.05 Control vs. cytokine treatment or stretch.

Journal: Matrix Biology Plus

Article Title: Temporal expression and spatial distribution of the proteoglycan versican during cardiac fibrosis development

doi: 10.1016/j.mbplus.2023.100135

Figure Lengend Snippet: Versican ( VCAN ) expression is regulated by cytokines and mechanical stretch in cardiac cells. (A) mRNA expression of versican was upregulated by TGF-β1, and downregulated by TNF-α, and IL-1β in cardiac fibroblasts, and (B) in addition by IL-4 in cardiomyocytes compared to control (Control, n = 3). (C, D) Versican and α-SMA ( ACTA2 ) mRNA expression were increased after biaxial strain of 10% (stretch) for 24 h at 1 Hz frequency in fibroblasts compared to non-stretched cells (Control, n = 9). Gene expression is presented as values relative to Control. Bar graphs represent mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test (A, B) and Student’s t -test (C, D) were used for statistical analysis. P values < 0.05 were considered statistically significant. *P < 0.05 Control vs. cytokine treatment or stretch.

Article Snippet: Fetal human cardiac fibroblasts (CFs) (Cell Applications, CA, #306-05F) and primary human cardiomyocytes (CMs) (PromoCell, Germany, #C-12810) were used for in vitro experiments.

Techniques: Expressing, Control, Gene Expression

a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 fibroblast, 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).

Journal: Nature

Article Title: The extracellular matrix protein agrin promotes heart regeneration in mice

doi: 10.1038/nature22978

Figure Lengend Snippet: a, b, Representative fields of heart cultures stained with DAPI (blue), cTnT (green) and Ki67 (red). White arrows indicate Ki67+cTnT+ cells. CMs, cardiomyocytes. c, d, Percentage of proliferating cardiomyocytes from P1 (c) or P7 (d) hearts in response to P1 and P7 ECM particles. n = 2,069 cardiomyocytes from three samples (c); n = 2,221 cardiomyocytes from four samples (d). e, f, Percentage of proliferating cardiomyocytes (Ki67+cTnT+) in response to P1 and P7 ECM in P1 (e) or P7 (f) cultures, with or without the broad MMP inhibitor (Marimastat). n = 3,480 cardiomyocytes from three samples (e); n = 23,445 cardiomyocytes from four samples (f). g, h, Percentage of P1 (g) or P7 (h) proliferating cardiomyocytes in response to MMP9- or MMP12-cleaved ECM fragments. n = 11,820 cardiomyocytes from four samples (g); n = 15,509 cardiomyocytes from four samples (h). i, qPCR of Agrn mRNA in P1 and P7 hearts. n = 8 P1 and 3 P7 hearts. j, Quantification of western blots for agrin from P1, P7 and 12-week-old (12W) adult heart lysates. A.U., arbitrary units. n = 3 samples per group. k, Images of P1 and P7 heart sections stained for agrin (green) and DAPI (blue). n = 3 samples per group. l, qPCR analysis of cardiac populations (FB, fibroblasts; CM, cardiomyocytes; EC, endothelial cells). n = 4 cardiomyocyte, 4 non-cardiomyocyte, 4 fibroblast, 4 non-fibroblast, 7 endothelial cells and 7 non-endothelial cell samples. Scale bars, 40 μm (a) and 10 μm (k). Data are presented as mean ±s.e.m. *P < 0.05, **P< 0.01, ***P< 0.001; statistical significance was calculated using ANOVA followed by a Dunnett’s post hoc test relative to the control group (c–h) or a Tukey’s post hoc test (j), statistical significance was calculated using a one-tailed t-test (i, l).

Article Snippet: Separation to distinct cardiac cell populations was performed by using the Neonatal Cardiac Endothelial Cell Isolation kit (130-104-183, Miltenyi Biotec), Neonatal Cardiac Fibroblast Cell Isolation kit (130-101-372, Miltenyi Biotec) or by Neonatal Cardiomyocyte Isolation kit (130-100-825, Miltenyi Biotec), according to the manufacturer’s instructions.

Techniques: Staining, Western Blot, Control, One-tailed Test